Partnership will support the development of investigational drug telacebec for the treatment of tuberculosis, leprosy, and Buruli ulcer NEW YORK
NEW YORK (September 12, 2025)—Lupin Limited, a leading pharmaceutical company headquartered in India, has been granted prequalification by the World
Stop TB Canada has announced a streamlined process to speed up the availability of pretomanid, a key drug in the
Throughout 2024, one of TB Alliance’s foremost priorities has been ensuring that pretomanid and BPaL-based regimens reach all people with
NEW YORK (November 6, 2024) — Macleods, a pharmaceutical company headquartered in India, has received prequalification from the World Health
NEW YORK (November 13, 2023)—Indian pharmaceutical company Macleods has become the second manufacturer to launch pretomanid, a new medicine and
NEW YORK (August 10, 2023)—Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license
Agreement between non-profit product development partnership and multinational pharmaceutical company will expand access to new TB drug NEW YORK and
Pretomanid is only the third new anti-tuberculosis (TB) drug developed specifically for drug-resistant forms of the disease to be approved
The NPAP is designed for patients in countries where regulatory approval or other access mechanisms for pretomanid are not yet
